Latest Breaking News On - Haywood miller - Page 4 : comparemela.com

After Cyfendus full approval, Emergent clinches $75M anthrax vaccine supply pact in US

After Cyfendus full approval, Emergent clinches $75M anthrax vaccine supply pact in US
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

United statesHaywood millerRobert kramerBiomedical advanced researchUs department of healthHuman servicesBerkely research groupDevelopment authorityEmergent biosolutionsBerkely research

Emergent BioSolutions (EBS) Q3 2023 Earnings Call Transcript

EBS earnings call for the period ending September 30, 2023.

United statesPaul williamsFrank dilorenzoHaywood millerNeal fowlerDon degolyerDrug administrationSingular researchStrategic nationalEmergent biosolutionsRich lindahlChief executiveMotley fool stock advisorStock advisorVice presidentChief financial

Emergent BioSolutions Inc (NYSE:EBS) Q3 2023 Earnings Call Transcript

Operator: Good afternoon, everyone. I am the operator for today’s call. Thank you for joining today as Emergent discusses the Operational and Financial Results for the Third Quarter of 2023.

United statesDon degolyerHaywood millerPaul williamsNeal fowlerEmergent biosolutions incDrug companiesDrug administrationEmergent biosolutionsCall transcript novemberFinancial resultsThird quarterInterim chief executive officerProduct businessRich lindahlChief financial officer

Emergent BioSolutions Reports Third Quarter 2023 Financial Results

Third Quarter 2023 Total Revenues of $271M, above the prior guidance rangeThird Quarter 2023 Pre-Tax Loss of $M and Adjusted EBITDA of $20MUpdates FY 2023 guidance GAITHERSBURG, Md., Nov. 08,.

United statesHaywood millerRidgeback biotherapeuticsAssal hellmerDevelopment expenses to adjusted researchDrug administrationBiomedical advanced researchCompany camdenStrategic nationalReconciliation of researchProduct service level revenueExchange commissionEmergent biosolutions incDevelopment expensesDevelopment authorityThird quarter

Emergent BioSolutions Reports Third Quarter 2023 Financial

Third Quarter 2023 Total Revenues of $271M, above the prior guidance rangeThird Quarter 2023 Pre-Tax Loss of $(266)M and Adjusted EBITDA(2) of $20MUpdates.

United statesHaywood millerAssal hellmerRidgeback biotherapeuticsDevelopment authorityExchange commissionEmergent biosolutions incDevelopment expensesProduct service level revenueReconciliation of researchCompany camdenStrategic nationalDevelopment expenses to adjusted researchDrug administrationBiomedical advanced researchThird quarter